CardioTech and Credent form deal on ChronoFlex RC
This article was originally published in Clinica
Executive Summary
CardioTech International has granted an exclusive worldwide licence of its IP rights for its ChronoFlex RC technology to UK company Credent Vascular Technologies, which will now be able to exclusively synthesise ChronoFlex RC biodurable polycarbonate-urethane, for the manufacture of vascular access and peripheral access grafts.